Skip to content

Mechanisms of Macrophage Polarization in HIRI in Patients With NAFLD

Mechanisms of Macrophage Polarization in Hepatic Ischemia-Reperfusion Injury in Patients With Non-Alcoholic Fatty Liver Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06950710
Enrollment
300
Registered
2025-04-30
Start date
2025-04-01
Completion date
2026-06-30
Last updated
2025-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Ischemia-reperfusion Injury, Non-alcoholic Fatty Liver Disease

Brief summary

To better understand the occurrence of hepatic ischemia-reperfusion injury (IRI) in patients with non-alcoholic fatty liver disease (NAFLD) and the role of macrophage polarization in this process, this study will retrospectively collect clinical data from patients who underwent partial hepatectomy at Beijing Tsinghua Changgung Hospital between September 2021 and March 2025. Additionally, clinical information and liver blood samples from patients scheduled for partial hepatectomy from April 2025 onward will be prospectively collected. These samples will include normal liver tissue from the resected portion, as well as 5 mL of venous blood obtained before and after surgery. The investigators will compare the severity of hepatic IRI, the expression of macrophage polarization-related proteins, and macrophage polarization markers in blood samples between NAFLD patients and controls. The study aims to determine whether NAFLD patients experience more severe hepatic IRI and to elucidate the role and mechanisms of macrophage polarization in this context. The findings will provide a theoretical basis for understanding the molecular mechanisms underlying hepatic IRI in NAFLD patients, thereby identifying potential therapeutic targets to prevent IRI and improve prognosis in NAFLD patients undergoing partial hepatectomy.

Interventions

OTHERNAFLD

This study is an observational one with no intervention

Sponsors

Zhifeng Gao
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The vital organ systems (heart, lungs and kidneys) have sufficient functional reserves.

Exclusion criteria

* No hepatic inflow occlusion (Pringle maneuver) was applied during surgery. * American Society of Anesthesiologists (ASA) Physical Status Classification \> Grade III. * Secondary causes of hepatic steatosis were excluded, including viral hepatitis, drug-induced liver injury, total parenteral nutrition, Wilson's disease, and autoimmune liver diseases. * Prior chemotherapy or radiotherapy before the planned surgery. * Use of anticoagulant medications.

Design outcomes

Primary

MeasureTime frameDescription
Concentration of transaminase7 days after the operationALT、AST

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026